Novel Treatments and the Future of Diabetic Nephropathy: What Is on the Horizon?

Batuman, Vecihi

doi:10.1007/978-1-4939-0793-9_19

Cited by 2 publications

(2 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5][6][7] Additionally, diabetes is present in approximately 30-40% of all cases of endstage renal disease (ESRD) in the USA. 8 The CKD staging system developed by the Kidney Disease Outcomes Quality Initiative (KDOQI) of the National Kidney Foundation (NKF) uses estimated glomerular filtration rates (eGFRs) to facilitate early identification and stage-specific diabetes treatment and dosing adjustment. Under this system, KDOQI recommended avoiding glyburide treatment in stages 3-5 of CKD, and initiating treatment with other agents, using appropriate dose adjustments, and urges special care with metformin.…”

Section: Introductionmentioning

confidence: 99%

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Bell

Stanford

et al. 2016

BMJ Open Diab Res Care

164

113

View full text Add to dashboard Cite

ObjectiveTo describe the estimated prevalence and temporal trends of chronic kidney disease (CKD) treatment patterns, and the association between CKD and potential factors for type 2 diabetes mellitus (T2DM) in different demographic subgroups.Research design and methodsThis was a cross-sectional analysis of adults with T2DM based on multiple US National Health and Nutrition Examination Survey (NHANES) datasets developed during 2007–2012. CKD severity was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines using the CKD Epidemiology Collaboration (CKD-EPI) equation: mild to moderate=stages 1–3a; moderate to kidney failure=stages 3b–5. Multivariable logistic regression analyses were performed to assess the associations between CKD and potential factors.ResultsOf the adult individuals with T2DM (n=2006), age-adjusted CKD prevalence was 38.3% during 2007–2012; 77.5% were mild-to-moderate CKD. The overall age-adjusted prevalence of CKD was 40.2% in 2007–2008, 36.9% in 2009–2010, and 37.6% in 2011–2012. The prevalence of CKD in T2DM was 58.7% in patients aged ≥65 years, 25.7% in patients aged <65 years, 43.5% in African-Americans and Mexican-Americans, and 38.7% in non-Hispanic whites. The use of antidiabetes and antihypertensive medications generally followed treatment guideline recommendations. Older age, higher hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and having hypertension were significantly associated with CKD presence but not increasing severity of CKD.ConclusionsCKD continued to be prevalent in the T2DM population; prevalence remained fairly consistent over time, suggesting that current efforts to prevent CKD could be improved overall, especially by monitoring certain populations more closely.

show abstract

Section: Introductionmentioning

confidence: 99%

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Bell

Stanford

et al. 2016

BMJ Open Diab Res Care

164

113

View full text Add to dashboard Cite

show abstract

“…11 The exact cause of DN is still unknown, but various mechanisms like hyperfilteration, renal injury, advanced glycation end products, and cytokines activation are involved in hyperglycaemia. 12 A wealth of evidence indicates that the renin-angiotensin system has a key role in the pathogenesis of DN. 13 Peripheral renin-angiotensin-aldosteron system (RAAS) gets overactivated during the DN.…”

Section: Introductionmentioning

confidence: 99%

Role of Brain Angiotensin (1-7) In Chronic Hyperglycaemia Induced Nephropathy in Wistar Rats

Shakya¹,

Goyal²,

Semwal³

et al. 2017

IJPER

View full text Add to dashboard Cite

Objective: Ang (1-7) recognised as a biologically active component of renin angiotensin system (RAS). It has been documented that peripheral activity of Ang (1-7) gets reduced during diabetic nephropathy (DN) which is one of the most common cause of end stage renal disease. Peripheral activity of RAS is regulated by brain RAS. The purpose of present study is to investigate the role of brain angiotensin (1-7) in chronic hyperglycemia induced nephropathy in wistar rats. Material and methods: Diabetes mellitus (DM) is induced by single dose of alloxan (120 mg/kg: i.p.). The biochemical parameters related to DN was estimated using commercially available kits. Results: Diabetic rat, after 8 weeks of alloxan administration shows elevated serum creatinine, blood urea nitrogen, protein in urine, kidney weight/body weight and deceased level of serum nitrite. However, intracerebroventricular treatment with Ang (1-7) (4.8 µg/day) and valsartan (100 nmol/ day) (which do not cross blood brain barrier) alone and combination of Ang (1-7) and valsartan for 2 weeks markedly attenuated these changes and increased serum nitrite in DN induced rats. Conclusion: The finding of this study suggests that brain Ang (1-7) play a vital role in controlling the peripheral activity of RAS in diabetic nephropathy which may be due to the decreased central sympathetic outflow and peripheral activity of Ang II.

show abstract

Novel Treatments and the Future of Diabetic Nephropathy: What Is on the Horizon?

Cited by 2 publications

References 105 publications

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012

Role of Brain Angiotensin (1-7) In Chronic Hyperglycaemia Induced Nephropathy in Wistar Rats

Contact Info

Product

Resources

About